Preparation and use of tumor antigen from pathological immunoglobulin for patients with multiple myeloma;Příprava a použití nádorového antigenu z patologického imunoglobulinu pro pacienty s mnohočetným myelomem

Transfuze a Hematologie Dnes

Volumn 8, Issue 3, 2002, Pages 91-95

  Musilova R ^a   Taborska E ^b   Bourkova L ^a   Buchler T ^a,c   Hanak L ^a   Kovarova L ^a,c   Novotna H ^d   Penka, M ^a   Hajek R ^a,c  

^a Bunecne Imunoterapie   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^d Oddeleni Klinicke Biochemie   (Czech Republic)

Author keywords

Affinity chromatography; Idiotypic protein; Monoclonal immunoglobulin

Indexed keywords

CANCER VACCINE; CHLORIDE; GLUTARALDEHYDE; GLYCINE; IDIOTYPIC ANTIBODY; IMMUNOGLOBULIN G; KEYHOLE LIMPET HEMOCYANIN; PARAPROTEIN; PROTEIN G;

ADULT; AFFINITY CHROMATOGRAPHY; AGED; ARTICLE; B LYMPHOCYTE; CANCER CELL; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG CONJUGATION; DRUG ISOLATION; DRUG SYNTHESIS; DRUG USE; ELUTION; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE MYELOMA; POLYACRYLAMIDE GEL ELECTROPHORESIS; URINE LEVEL; VACCINATION;

EID: 0038206767     PISSN: 12135763     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Hájek R, Vášová I, Adam Z, Mayer J. New approaches to management of multiple myeloma. Acta Medica Austriaca 1996; 23: 91-8.
2. Barlogie B, Jagannath S, Vesole DH, et al. Autologous and allogenic transplantation for multiple myeloma. Sem Oncol 1995; 32: 31-44.
3. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91-7.
4. Adam Z, Vorlíček J, Králová E, et al. Terapie mnohočetného myelomu (Therapy of multiple myeloma. Press: Opsula Haematologica, Masaryk University Brno, 1993; 1-220.
5. Adam Z, Hájek R, Mayer J, Ščudla V, Vorlíček J, a kol. Mnohočetný myelom a další monoklonální gamapatie. Masarykova univerzita, 1999.
6. Kwak LW, Taub DD, Duffey PL, Bensinger WI, Bryant EM, et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 1995; 345: 1016-20.
7. Bergenbrant S, Yi Q, Österborg A, Bjorkholm M, Osby E, et al. Modulation of anti-idiotypic immune responze by immunization with the autologous M-component protein in multiple myeloma patients. Brit J Haematol 1996; 92: 840-6.
8. Österborg A, Yi Q, Henriksson L, Fagerberg J, Bergenbrant S. Idiotype immunization combined with GM-CSF in myeloma patients induced type I, MHC-restricted, CD8- and CD4-specific T-cell responses. Blood 1998 Vol 91, No 7.
9. Titzer S, Christensen O, Manzke O, Tesch H. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clonical aspects. British Journal of Haematology 2000; 108: 805-16.
10. Massaia M, Borrione P, Battaglio S, Mariani S. Idiotype vaccination in human Myeloma: generation of tumor-specific immune responses after high- dose chemotherapy. Blood 1999; Vol 94, No 2.
11. Andersson M, Holm G, Lefvert AK, Mellstedt H. Anti-idiotypic B-cell lines from a patient with monoclonal gammopathy of undetermined significance. Scan j Immunol 1989; 30: 489-92.
12. Bergenbrant S, Österborg A, Holm G, et al. Anti-idiotypic antibodies in patients with monoclonal gammopathies: relation to the tumor load. Brit J Haematol 1991; 78: 66-70.
13. Wen YJ, Barlogie B, Yi Q. Idiotype-specific T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Blood 2001; 97 (6): 1750-5.
14. Steinman RM. Dendritic cells and immune-based therapies. Exp Haematol 1996; 24: 856-62.
15. Hájek R, Butch AW. Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma. Med Oncol 2000, 17: 2-15.
16. Henskens Y, Winter J, et al. Detection and identification of monoclonal gammopathies by capillary electrophoresis. Clinical Chemistry 1998; 44(6): 1184-90.
17. Jenkins M, Guerin MD. Capillary electrophoresis procedures for serum protein analysis: comparison with established techniques. Journal of Chromatography 1997; 699: 257-68.
18. Reichardt VL, Okada CY, Liso A. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - a feasibility study. Blood 1999; 94(2): 673-83.
19. Liso A, Stockerl-Goldstein KE, Auffermann-Gretzinger S, Benike C, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. J Biol Blood Marrow Transplant 2000; 6(6): 621-7.
20. Mellstedt H, Österborg A. Active idiotype vaccination in multiple myeloma; GM-CSF may be an important adjuvant cytokine. Path Biol 1999; 47: 211-15.
21. Dabadghao S, Bergenbrant S, Anton D, He W. Anti-idiotypic T-cell activation in multiple myeloma induced by M-component fragments presented by dendritic cells. British Journal of Haematology 1998; 100: 647-54.
22. Hájek R, Křivanová A, Bourková L, et al. Biologie dendritických buněk a jejich příprava pro klinické užití (přehled a předběžné výsledky ). Klinická onkologie 2001; 14: 79-84.
23. Ruffini PA, Kwak LW. Immunotherapy if Multiple Myeloma. Seminars of Hematology 2001; 38: 260-67.
24. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or lysate-pulsed dendritic cells. Nat Med 1998; 4: 328.
25. Brossart P, Heinrich KS, Stuhler G, et al. Identification of HLA-A2- restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 1999; 93: 4309.
26. Brosart P, Wirths S, Brugger W, Kenz I. Dendritic cells in cancer vaccines. Exp Hematol 2001; 29: 1247-55.